All In Biotech

Drug Trial Radar · NCT07027111

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

14

Actual

Start

Apr 25, 2025

Primary completion

Oct 1, 2026

Study completion Oct 1, 2026

Sponsor

Lead sponsor
Nuvig Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to potentially help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

  • NVG-2089Drug

    Study drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate incidence, nature and severity of TEAE'sTime frame: Week 14
  2. Evaluate incidence, nature and severity of SAE'sTime frame: Week 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nuvig Site

    Denton, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.